Pleasant Odors for Craving
(OdorCrave Trial)
Trial Summary
What is the purpose of this trial?
The proposed study uses fMRI and behavioral measures in and outside the laboratory to investigate the neurobehavioral mechanisms underlying the impact of pleasant olfactory cues (OCs) on cigarette craving. The investigators plan to randomize 278 participants to a pleasant OC condition or an odor blank (neutral) condition and due to anticipated drop out expect to run 250 adult (half female) smokers, including both daily and nondaily smokers through the protocol. This study involves three visits. In the first visit, participants will complete a baseline breath carbon monoxide reading, a brief odor threshold test, and complete a series of self-report measures. In the next session, participants who are 8-hrs deprived of nicotine will undergo a 60-minute fMRI scan that will include structural, resting state, and task-based data collection. The fMRI task involves completing a series of tasks designed to index responses linked to key neural networks found to relate to addiction (e.g., reward processing, working memory). Participants will also be exposed to smoking cues to heighten craving and then depending on their condition (randomly assigned) will either receive a pleasant or neutral (odor blank) OC. In the third session, behavioral data will be collected to test the impact of either a pleasant or neutral OC on cigarette craving using self-reported urge and behavioral measures linked to craving. Finally, for pilot purposes designed to offer data for a subsequent clinical study (beyond this study), participants will additionally complete a 7-day ecological momentary assessment (EMA) protocol in which they will monitor cigarette craving and initial data will be collected outside the laboratory to evaluate the impact of OCs on naturally occurring craving. It is hypothesized that pleasant OCs will disrupt craving brain states and attenuate craving (as compared to neutral olfactory cues). Further, it is hypothesized that individual variation in neural responses to cognitive and affective tasks will reveal variation in mechanisms underlying pleasant OC craving reduction and that individual differences will moderate pleasant OC-induced craving relief. Finally, it is also expected that emotional responses to pleasant OCs will mediate the impact of OCs on craving and smoking-related processes.
Will I have to stop taking my current medications?
The trial does not specify if you need to stop taking your current medications, but it does exclude those with current psychoactive drug use and drug dependence outside of nicotine or caffeine.
What data supports the effectiveness of the treatment Pleasant Odors for Craving?
Research shows that pleasant smells can help reduce cravings, such as cigarette cravings, by providing a positive sensory experience that distracts from the urge. In one study, smokers who smelled pleasant odors reported less craving compared to those exposed to neutral or tobacco-related smells.12345
Is it safe to use pleasant odors for reducing cravings?
How does the Pleasant Odor treatment differ from other treatments for cravings?
The Pleasant Odor treatment is unique because it uses pleasant smells to reduce food cravings by engaging the brain's limited-capacity resources, which is different from traditional methods that might involve medication or dietary changes. This approach leverages the brain's response to pleasant scents to curb cravings, offering a non-invasive and sensory-based alternative.910111213
Research Team
Marc N Coutanche, PhD
Principal Investigator
The University of Pittsburgh
Michael A Sayette, PhD
Principal Investigator
The University of Pittsburgh
Eligibility Criteria
This trial is for right-handed, English-speaking adults aged 18-49 who smoke cigarettes daily (10-30 per day) or nondaily. They must weigh less than 250lbs to fit in an MRI machine safely, have a working smartphone, and an intact sense of smell. Smokers with extreme habits or other drug dependencies besides nicotine or caffeine are excluded.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Baseline Assessment
Participants complete a baseline breath carbon monoxide reading, odor threshold test, and self-report measures
fMRI Session
Participants undergo a 60-minute fMRI scan including structural, resting state, and task-based data collection
Behavioral Session
Participants complete behavioral tasks to assess the impact of olfactory cues on cigarette craving
Ecological Momentary Assessment (EMA)
Participants monitor cigarette cravings over a 7-day period to evaluate the impact of olfactory cues on naturally occurring craving
Follow-up
Participants are monitored for safety and effectiveness after the main study procedures
Treatment Details
Interventions
- Odor Blank
- Pleasant Odor
Find a Clinic Near You
Who Is Running the Clinical Trial?
University of Pittsburgh
Lead Sponsor
National Center for Complementary and Integrative Health (NCCIH)
Collaborator